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With great interest we read the paper of Khalil and Läer
on the concepts of physiologically based pharmacokinetic
(PBPK) modeling and its applications to pediatric drug
development [1]. The authors clearly described the methodology, applications, and limitations of PBPK models in
pediatric drug development [1]. In essence, PBPK models
hold the promise to design and perform a pediatric study
based on “a well-educated guess” to paraphrase what the
authors refer to as “confirmatory” instead of “exploratory”
approach. The approach described by the authors hereby
mainly reflects what we would like to describe as a “topdown (from model to clinical observations)” concept: based
on the available knowledge on developmental anatomy and
physiology, a PBPK model is developed, undergoes validation, and will subsequently facilitate pediatric studies [1]. We
would like to further challenge research groups active in the
field of PBPK modeling not to get too disconnected from
the “in vivo” world of pediatric developmental pharmacology
and also consider what we would like to describe as a
“bottom-up (from clinical observations to model)” concept:
from compound specific observations to mechanism-based
models [2–5]. It is our strong opinion that active comparison
between PBPK and mechanism based models using the same
in vivo datasets can be helpful to further improve clinical

care but also provides guidance for more focused studies on
aspects of developmental physiology.
During the last 2-3 decades, hundreds of compound specific clinical pharmacology studies have been conducted to
investigate the impact of ontogeny on clinical pharmacology
in pediatric populations.
As clinical pharmacologists and neonatologists with
specific interest in developmental pharmacology, we would
like to raise awareness for the relevance of “rich data sets”
that contain both clinical characteristics and concentrationtime (pharmacokinetics) or concentration-eﬀect (pharmacodynamics) profiles [6]. The description of a compound
specific pattern is beyond compound specific relevance
(“bottom-up”) [1–5]. The maturational patterns described
and the extent of the impact of covariates can subsequently
be applied to predict in vivo concentration-time profiles
for compounds that undergo similar routes of elimination. Through improved predictability, such maturational
mechanism-based models can serve to improve clinical care
and feasibility of clinical studies in neonates. The same
in vivo observations can also be used as a “bottom-up”
approach to learn more about the maturational patterns, and
to guide research on gaps in the knowledge on developmental
anatomy and physiology.
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Figure 1: Integration of in vivo datasets analyzed by mechanism-based and PBPK predictive models results in a switch from “explorative,
hypothesis-driven” to “confirmative” approach in the field of developmental physiology. This is illustrated for renal drug clearance in
neonates, which reflects glomerular filtration rate (e.g., aminoglycosides) or a more complex pattern of known (glomerular filtration rate,
protein binding) and still unknown (renal tubular transport ontogeny) (e.g., cefazolin) maturational processes.

The concept of a comparative approach using both
PBPK and mechanism-based models for drugs cleared by
renal elimination is illustrated in Figure 1. In the left
panel of Figure 1, a mechanism-based approach (bottom-up:
description based on observations, subsequent validation) is
considered, in the right panel, a PBPK-based approach (topdown: development of a PBPK model based on renal maturational physiology data, that is, ontogeny of glomerular
filtration rate [GFR] is applied). Based on mechanism-based
models, we described covariates of amikacin and vancomycin
clearance in 531 neonates and documented that size, postmenstrual age, growth restriction, and coadministration of
ibuprofen explained 85% of the interindividual variability in
clearance [7]. The same amikacin dataset has more recently
been used to validate a PBPK model (left panel, Figure 1) that
aimed to describe maturational GFR in (pre)term neonates
[8].
Both approaches should describe GFR ontogeny. However, when these PBPK-GFR models are subsequently used
to predict renal elimination clearance of compounds that do
not only depend on GFR, but also on protein binding and
renal tubular functions (e.g., cefazolin), the PBPK models
will fail because data on renal tubular ontogeny are not yet
available. In contrast, the use of mechanism-based models
to describe the covariates of cefazolin clearance in such a
dataset and comparison with the PBPK-GFR model may
unveil thresholds and patterns of renal tubular maturation
that can subsequently guide researchers to explore ontogeny
of renal tubular activity in specific subpopulations, resulting
in a similar confirmatory instead of exploratory approach.
In conclusion, similar to PBPK models for clinical care
(top-down), mechanism-based models (bottom-up) and
comparison between both approaches may further guide and
facilitate both clinical and fundamental research on developmental physiology and anatomy [1–5]. Discrepancies serve

as indicators for “missing” links in our knowledge on maturational anatomy or physiology (e.g., drug receptor activity,
receptor expression) and in this way may also shape fundamental research in the field of developmental physiology. In
this way, PBPK models do not only hold the promise (topdown) to be helpful in the clinical design, but may also serve
as indicators to perform developmental anatomy/physiology
research projects as “confirmatory” instead of “exploratory.”
In this way, improved knowledge on developmental pharmacology does not only serve the individual clinician and the
patient, but can also improve focused fundamental research
on aspects of developmental biology that are currently hardly
understood and diﬃcult to explore.
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